- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03752892
Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis
Randomized Controlled Trial of Partitioned Aerobic Exercise Training of Patients With Idiopathic Pulmonary Fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dyspnea is a major clinical manifestation of idiopathic pulmonary fibrosis (IPF). It becomes more severe and more limiting as the condition progresses. Many professional respiratory societies recommend that the standard of care for IPF includes pulmonary rehabilitation (PR). However, some patients with IPF are so limited by dyspnea that they are unable to tolerate levels of aerobic exercise training sufficient to induce the physiological adaptations that will improve functional and health related outcomes. Therefore, there is a need for exercise training interventions that will enhance the muscle training stimulus above that currently possible in individuals with a marked ventilatory limitation.
Partitioning large muscle exercise using one-legged high intensity training is more effective than conventional aerobic training when applied to patients with central ventilatory or cardiac limitation. Effective partitioned exercise enables an increased muscle load with less ventilatory load. It increases the training stimulus to the muscles as they work at a high intensity, relative to their current aerobic state, necessary to increase their capacity. As long as the active muscle mass can create the same demands on the central exercise components of the heart and circulation as does conventional two-legged exercise, this simple, inexpensive novel approach, will stimulate leg muscles sufficiently to improve overall cardiorespiratory fitness. For example, in those with chronic obstructive pulmonary disease, one-legged training has been shown to provide a muscle specific stimulus sufficient to improve whole body peak oxygen uptake during pulmonary rehabilitation. A preliminary acute study of patients with IPF has demonstrated that during a laboratory simulation of an exercise training session, partitioning aerobic exercise extended exercise tolerance. Participants achieved double the work whilst exercising with one leg compared with two-legged cycle exercise. Partitioned training may therefore be an effective approach to exercise training in patients with IPF enrolled in PR.
The advent of pharmacological agents that stabilize the clinical course of IPF presents a window of opportunity for exercise rehabilitation to further improve function. The aim of this proposed study is to determine whether, within the setting of PR, partitioned aerobic exercise training with a one-legged cycle training regime is more effective than the conventional two-legged regimen in increasing exercise tolerance. The study hypothesis is that partitioned aerobic exercise training, using a one-legged training regime is more effective than conventional two-legged exercise training in increasing exercise tolerance (measured by constant power endurance) and cardiorespiratory fitness as measured by maximal oxygen uptake. The results will inform the best approach to produce clinically meaningful improvements in dyspnea and health status for those with IPF.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tom Dolmage
- Phone Number: 2185 1-416-243-3600
- Email: tom.dolmage@westpark.org
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M6M 2J5
- Recruiting
- West Park Healthcare Centre
-
Contact:
- Tom Dolmage
- Phone Number: 4162433600
- Email: tom.dolmage@westpark.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- confirmed idiopathic pulmonary fibrosis
- Clinically stable
- enrolled in pulmonary rehabilitation
Exclusion Criteria:
- co-morbidities that might impair their ability to safely complete a pulmonary rehabilitation program
- complete a pulmonary rehabilitation program within the previous 6 months
- experienced an exacerbation less than six weeks before participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intervention -1-leg cycle training
Primary aerobic training component one-legged, partitioned, cycle training.
A progressive approach to combined intensity and duration will be taken.
A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
|
partitioned aerobic exercise training
|
Active Comparator: usual care - 2-leg cycle training
Primary aerobic training component conventional two-legged cycle training.
A progressive approach to combined intensity and duration will be taken.
A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
|
conventional aerobic exercise training
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cycle exercise endurance time
Time Frame: Change from Baseline at discharge from 8 weeks of pulmonary rehabilitation
|
tolerance (time) of a constant power high intensity cycle endurance test
|
Change from Baseline at discharge from 8 weeks of pulmonary rehabilitation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
health-related quality of life
Time Frame: Change from Baseline at discharge from 8 weeks of pulmonary rehabilitation
|
using the questionnaire 'A Tool to Assess Quality of life in IPF' [ATAQ-IPF]
|
Change from Baseline at discharge from 8 weeks of pulmonary rehabilitation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1L-IPF-RCT-RG2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung; Disease, Interstitial, With Fibrosis
-
Pediatric Clinical Research PlatformUniversity Hospital, Geneva; Swiss Federal Institute of Technology; Hôpital du...RecruitingPulmonary Disease, Chronic Obstructive | Artificial Intelligence | Lung; Disease, Interstitial, With FibrosisSwitzerland
-
University of British ColumbiaCompletedLung; Disease, Interstitial, With FibrosisCanada
-
Duke UniversityBoehringer IngelheimRecruitingIdiopathic Pulmonary Fibrosis, Interstitial Lung DiseaseUnited States, Puerto Rico
-
University of DundeeBritish Lung Foundation; Newcastle University; University of Leicester; University... and other collaboratorsActive, not recruitingIdiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias | Alveolitis, Extrinsic Allergic | Lung; Disease, Interstitial, With Fibrosis | Bird Fancier's LungUnited Kingdom
-
Pulmonary Fibrosis FoundationUniversity of MichiganCompletedInterstitial Lung Disease (ILD) | Idiopathic Pulmonary Fibrosis (IPF)United States
-
KU LeuvenCompletedInterstitial Lung Disease | Interstitial Pulmonary FibrosisBelgium
-
Sunshine Lake Pharma Co., Ltd.RecruitingProgressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)China
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Heidelberg UniversityLungenfibrose e.V.CompletedIdiopathic Pulmonary Fibrosis | Fibrosing Interstitial Lung DiseasesGermany
-
Andreas GuentherActive, not recruitingIdiopathic Pulmonary Fibrosis | Idiopathic Interstitial Pneumonia | Interstitial Lung Diseases | Diffuse Parenchymal Lung DiseasesUnited Kingdom, Germany, Austria, Italy, France
Clinical Trials on intervention -1-leg cycle training
-
Kyoto UniversityCompletedElderly | Congestive Heart Failure | Endothelium-derived FactorsJapan
-
University of AlbertaAlberta Innovates Health SolutionsCompleted
-
University of MiamiEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMetabolic Syndrome | Spinal Cord Injuries | Tetraplegia | Dietary Modification | ParaplegiaUnited States
-
McMaster UniversitySt. Joseph's Healthcare HamiltonCompletedRespiratory Failure | Critical Care | Mechanical Ventilation | Intensive Care Unit Acquired WeaknessCanada
-
Horsholm MunicipalityRecruitingSarcopenia | Hip Fractures | Fall InjuryDenmark
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHealthy | Pulmonary Arterial HypertensionUnited States
-
University of ManitobaCanadian Institutes of Health Research (CIHR)CompletedAnterior Cruciate Ligament InjuryCanada
-
National Taiwan University HospitalUnknown
-
Shenzhen TargetRx, Inc.First Affiliated Hospital Bengbu Medical CollegeCompleted
-
University of Colorado, DenverCompleted